|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80-100%
|
|
gptkbp:blackBoxWarning
|
spinal/epidural hematoma risk
increased risk of thrombotic events after premature discontinuation
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:developedBy
|
gptkb:Bayer
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:eliminationHalfLife
|
5-9 hours (young), 11-13 hours (elderly)
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
GQSPXLAQXDMYIE-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:hasPatentExpiry
|
2024 (US)
|
|
gptkbp:hasSMILES
|
CC1=C(C=C(C=C1)Cl)S(=O)(=O)NC(=O)C2=CN=C(N=C2)OC3=CC=CC=C3C(=O)O
|
|
gptkbp:hasUNII
|
Y6O7T4G8P9
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB05509
|
|
gptkbp:indication
|
prevention of venous thromboembolism after hip or knee replacement surgery
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
gptkb:Factor_Xa_inhibitor
|
|
gptkbp:metabolism
|
hepatic (CYP3A4, CYP2J2, CYP-independent mechanisms)
|
|
gptkbp:molecularWeight
|
435.88
|
|
gptkbp:name
|
gptkb:Rivaroxaban
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2010604
gptkb:DB05509
8056452
9875401
D08917
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
allergic reactions
dyspepsia
|
|
gptkbp:synonym
|
gptkb:BAY_59-7939
|
|
gptkbp:target
|
gptkb:Factor_Xa
|
|
gptkbp:bfsParent
|
gptkb:Krystexxa
|
|
gptkbp:bfsLayer
|
8
|